A phase 2 study evaluated the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263), with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Authors

• Person: Not available Organization: Nature
  Cellular rejuvenation: molecular mechanisms and potential ... - Nature

Sources

• Cellular rejuvenation: molecular mechanisms and potential ... - Nature www.nature.com Nature via serper

Referenced by nodes (1)

• chronic lymphocytic leukemia concept